The clinical applications of TPL are limited by its narrow therapeutic window and severe toxicity on the digestive, reproductive, urogenital and blood circulatory systems. Recently, researchers have looked into the ability of TPL to enhance drug sensitivity. Our work has demonstrated the ability of TPL to enhance the sensitivity of resistance myeloid leukemia cell lines to drugs, indicating the probability of the usage of TPL as the drug sensitizer in the myeloid leukemia treatment. In the near future, samples from patients should be tested and in vivo studies will be undertaken to clarify whether patients carrying certain genes are more susceptible to TPL-induced drug sensitivity. Furthermore, clinical trials might be undertaken to further look into this issue to predict the treatment outcome of patients using TPL as a drug sensitizer.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.
Pharmacogenomics. 2013;14(11):1305-1317. © 2013 Future Medicine Ltd.